(MENAFN- Swissinfo) Readers asked us a host of questions about antibiotics amid rising rates of antimicrobial resistance and a lack of investment in new drugs to fight bacterial infections. We have some answers. This content was published on November 20, 2025 - 17:13 8 minutes

I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer. I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo in 2018, I was a freelance journalist and a researcher on business and human rights.

• More from this aut
• English Departm

My work focuses on engaging with you, our audience, and strengthening trust in our journalism. I develop engagement tools such as multilingual debates and help distribute our content to users across platforms. A former nurse, I later pursued English linguistics and media studies where I developed a keen interest in journalism and news in the digital age.

• More from this aut
• English Departm

Antibiotics transformed modern medicine and helped double the average human lifespan in the last century. But bacteria evolve to outsmart drugs designed to kill them.

Dangerous infections that no longer respond to antibiotics are spreading quickly around the world, by as much as 15% a year, according to a report by the World Health Organization (WHO) published in October. In 2023, one in six bacterial infections was already resistant to antibiotic treatments.

More More New treatments Swiss inaction threatens global antibiotic development push

This content was published on Jul 8, 2025 Switzerland risks stalling global antibiotic innovation amid rising resistance.

Read more: Swiss inaction threatens global antibiotic development

MENAFN20112025000210011054ID1110375235